A file image showing a person applying eyedrops on November 24, 2011 in Margaret River, Australia.

...

Sam Stevenson

By Sam Stevenson

Associate News Editor

0

Share

Newsweek is a Trust Project member

See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.


More than 3.1 million bottles of eye drops sold across the U.S. are under recall after the U.S. Food and Drug Administration (FDA) formally classified the action with an official risk level, weeks after the products were first pulled over sterility concerns.

K.C. Pharmaceuticals announced the voluntary recall earlier this month after identifying a potential manufacturing issue.

The FDA has now reviewed the case and assigned a Class II classification, formally assessing the level of risk posed by the products.

Read More on Health

Newsweek has contacted K.C. Pharmaceuticals, Inc. for comment via a form on its website.

A file image showing a person applying eyedrops on November 24, 2011 in Margaret River, Australia.

...

What To Know

The recall involves a wide range of over‑the‑counter eye drop products manufactured by K.C. Pharmaceuticals, Inc., based in Pomona, California.

According to FDA records, the products were distributed nationwide and sold under multiple brand names through major retailers, including Walgreens, Kroger, CVS, H‑E‑B, Cardinal Health distributors, military exchanges, and other outlets.

The stated reason for the recall is a “lack of assurance of sterility.”

FDA records indicate that sterility could not be guaranteed for the affected products, prompting the company to voluntarily remove them from the market.

In total, more than 3.1 million bottles are impacted. The recalled products include:

Each product listing includes specific lot numbers and expiration dates, which are detailed in the FDA’s report.

The recall is identified under multiple recall numbers, including D‑0409‑2026 through D‑0416‑2026, all associated with FDA Event ID 98533.

According to the agency, the recall was voluntarily initiated by the firm, and initial notifications were sent by email.

FDA records show the recall was initiated on March 3, 2026, by the firm and the FDA assigned its Class II classification on March 31, 2026.

The recall remains ongoing, and no termination date has been listed.

What Is a Class II Recall?

The FDA uses a Class II recall designation when use of or exposure to a product may cause temporary or medically reversible adverse health consequences, or when the probability of serious health effects is considered remote.

This classification reflects the FDA’s assessment after reviewing the circumstances of the recall.

While it is not the agency’s most severe category, a Class II designation still signals a meaningful safety concern that warrants consumer attention.

What Consumers Should Know

No official press release has been issued by the firm concerning this particular recall. The FDA advises consumers to check product labels, lot numbers, and expiration dates to determine whether they have purchased any of the recalled eye drops.

Additional details, including UPCs, are listed in the agency’s classification report.

The recalling firm is K.C. Pharmaceuticals, Inc., located in Pomona, California.

View 0 Comments

Request Reprint & Licensing

Submit Correction

View Editorial & AI Guidelines